154 related articles for article (PubMed ID: 34236934)
1. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
Leonardi C; Tao R; Setayeshgar S; Wang S; Burge R; Zhu B; Malatestinic WN
J Dermatolog Treat; 2022 Jun; 33(4):2278-2284. PubMed ID: 34236934
[TBL] [Abstract][Full Text] [Related]
2. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
Blauvelt A; Shi N; Murage M; Ridenour T; Lew C; Somani N; Zhu B; Zimmerman N; Kern S; Burge R
J Drugs Dermatol; 2022 Apr; 21(4):399-407. PubMed ID: 35389589
[TBL] [Abstract][Full Text] [Related]
5. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
Zidane M; Dressler C; Gaskins M; Nast A
JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
[TBL] [Abstract][Full Text] [Related]
8. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
[TBL] [Abstract][Full Text] [Related]
9. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
[TBL] [Abstract][Full Text] [Related]
12. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
Smolen JS; Sebba A; Ruderman EM; Schulze-Koops H; Sapin C; Gellett AM; Sprabery AT; Li L; de la Torre I; Gallo G; Liu-Leage S; Pillai S; Reis P; Nash P
Rheumatol Ther; 2020 Dec; 7(4):1021-1035. PubMed ID: 33200394
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
[TBL] [Abstract][Full Text] [Related]
15. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
Lebwohl MG; Gordon KB; Gallo G; Zhang L; Paul C
J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):301-309. PubMed ID: 31479549
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
17. Ixekizumab four-week dosing is comparable to two-week dosing in psoriasis patients and reduces treatment costs: experience in a real-world setting over a 12-week period.
Li Y; Yu Y; Wang Y; Lu J; Yi X; Yu N; Ding Y; Shi Y
Eur J Dermatol; 2022 Sep; 32(5):618-622. PubMed ID: 36468729
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
Reich K; Pinter A; Lacour JP; Ferrandiz C; Micali G; French LE; Lomaga M; Dutronc Y; Henneges C; Wilhelm S; Hartz S; Paul C;
Br J Dermatol; 2017 Oct; 177(4):1014-1023. PubMed ID: 28542874
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies.
Combe B; Tsai TF; Huffstutter JE; Sprabery AT; Lin CY; Park SY; Kronbergs A; Hufford MM; Nash P
Arthritis Res Ther; 2021 Jan; 23(1):41. PubMed ID: 33499913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
